Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Dyne Therapeutics (DYN) announced promising developments on March 10, 2022, regarding its clinical trials for DYNE-251 and DYNE-101, aimed at treating Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company reported a cash position of $376.6 million, sufficient to fund operations into the second half of 2024. However, it faced a net loss in Q4 2021 of $51.8 million, up from $28.6 million in Q4 2020, reflecting increased R&D expenses totaling $42.3 million. Clinical trial patient dosing is anticipated to start in mid-2022.
- Cash position of $376.6 million, funding operations into the second half of 2024.
- Initiation of patient dosing for DYNE-251 and DYNE-101 planned in mid-2022.
- Net loss increased to $51.8 million in Q4 2021 from $28.6 million in Q4 2020.
- R&D expenses rose significantly to $121.3 million in 2021 compared to $45.2 million in 2020.
- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Planned in Mid-2022 -
WALTHAM, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2021 and recent business highlights.
“In 2021 we made significant achievements throughout the business. We generated platform-validating preclinical data across our programs, including demonstrating sustained knockdown of toxic nuclear DMPK RNA and correction of splicing in DM1 and robust exon skipping and dystrophin expression in DMD. We also submitted our first IND for DYNE-251 in DMD in the fourth quarter, further strengthened our leadership team with multiple key hires, and completed a
Recent Highlights
- In December 2021, Dyne submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51. As previously announced, Dyne received a clinical hold letter from the FDA on January 14, 2022 requesting additional clinical and non-clinical information for DYNE-251. The Company expects to submit its response to the FDA in the second quarter of 2022 with data from existing and ongoing studies, and if satisfactory to the FDA, plans to begin dosing patients in a Phase 1/2 global multiple ascending dose (MAD) clinical trial of DYNE-251 in mid-2022.
- In recognition of Rare Disease Day, held annually on the last day of February, Dyne hosted individuals and families living with DMD, myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Their perspectives are featured in a video available here: https://www.dyne-tx.com/rdd2022/.
- On March 3, 2022, the Company announced the appointment of Carlo Incerti, M.D., to its Board of Directors. Dr. Incerti brings to Dyne more than three decades of experience in the biopharmaceutical industry, including in global rare disease drug development.
Upcoming Events and Milestones
- Preclinical data from Dyne’s DM1 and DMD programs that were presented during the World Muscle Society Virtual Congress and Muscle Study Group Annual Scientific Meeting in fall 2021 will be featured in encore presentations during the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 13-16, 2022, and will be available to registered attendees at https://mdaconference.org/.
- Dyne management is scheduled to participate in a virtual fireside chat during Stifel’s 4th Annual CNS Day on March 28, 2022 at 1:00 p.m. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
- The Company expects to submit its response to the FDA for the DYNE-251 IND in DMD in the second quarter of 2022 with the goal of dosing patients in a Phase 1/2 global MAD clinical trial in mid-2022.
- Dyne now plans to submit regulatory filings in multiple countries for DYNE-101 in DM1 in the second quarter of 2022, and in accordance with its previous guidance, expects to initiate patient dosing in a global MAD clinical trial in mid-2022.
- Dyne expects to submit an IND for DYNE-301 in FSHD in the second half of 2022.
Fourth Quarter and Full Year 2021 Financial Results
Cash position: Cash, cash equivalents and marketable securities were
Research and development (R&D) expenses: R&D expenses were
General and administrative (G&A) expenses: G&A expenses were
Net loss: Net loss for the quarter ended December 31, 2021 was
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of therapeutic programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the expected timeline for submitting its response to the FDA’s clinical hold letter, submitting regulatory filings and dosing patients in trials and the anticipated design of the trials, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; uncertainties as to the timing of and Dyne’s ability to submit and obtain regulatory clearance for investigational new drug applications and other regulatory filings and initiate clinical trials, including with respect to its response to the DYNE-251 clinical hold letter and its ability to obtain regulatory clearance of the DYNE-251 IND; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether investigators and regulatory agencies will agree with the design of Dyne’s planned clinical trials; whether Dyne’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties associated with the impact of the COVID-19 pandemic on Dyne’s business and operations; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
| Dyne Therapeutics, Inc. | ||||||||||||||||||
| Condensed Consolidated Statement of Operations | ||||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | $ | 42,304 | $ | 22,098 | $ | 121,308 | $ | 45,200 | ||||||||||
| General and administrative | 9,658 | 6,502 | 28,717 | 13,477 | ||||||||||||||
| Total operating expenses | 51,962 | 28,600 | 150,025 | 58,647 | ||||||||||||||
| Loss from operations | (51,962 | ) | (28,600 | ) | (150,025 | ) | (58,647 | ) | ||||||||||
| Other (expense) income, net | 175 | (49 | ) | 734 | (790 | ) | ||||||||||||
| Net loss | $ | (51,787 | ) | $ | (28,649 | ) | $ | (149,291 | ) | $ | (59,437 | ) | ||||||
| Net loss per share—basic and diluted | $ | (1.00 | ) | $ | (0.64 | ) | $ | (2.93 | ) | $ | (4.13 | ) | ||||||
| Weighted-average common shares outstanding used in net loss per share—basic and diluted | 51,543,053 | 45,058,494 | 50,895,044 | 14,395,955 | ||||||||||||||
| Dyne Therapeutics, Inc. | ||||||
| Condensed Consolidated Balance Sheet Data | ||||||
| (in thousands) | ||||||
| December 31, | December 31, | |||||
| 2021 | 2020 | |||||
| Assets | ||||||
| Cash, cash equivalents and marketable securities | $ | 376,571 | $ | 345,314 | ||
| Other assets | 49,092 | 8,020 | ||||
| Total assets | $ | 425,663 | $ | 353,334 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Liabilities | 57,466 | 10,967 | ||||
| Stockholders’ equity | 368,197 | 342,367 | ||||
| Total liabilities and stockholders’ equity | $ | 425,663 | $ | 353,334 | ||
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
What are the recent developments for Dyne Therapeutics (DYN) regarding DYNE-251 and DYNE-101?
What is the financial status of Dyne Therapeutics as of Q4 2021?
What is the anticipated timeline for the FDA submission for DYNE-251?
How did Dyne Therapeutics' R&D expenses change in 2021?
What was the net loss reported by Dyne Therapeutics for the full year 2021?
